0
Position
Consultant
Organization
N/A
Location
New York NY UNITED STATES
Bio
Member of Several Advisory Boards, Chair of RWE Advisory Board for SHYFT Analytics
Marc L. Berger, M.D. retired in July 2017 after serving for 5 years as Vice President, Real World Data and Analytics at Pfizer, Inc. He joined SHYFT Analytics as Chair of the Real World Evidence Product Advisory Board in September 2017. In June 2018, he became an advisor at EvidScience, Inc. In September 2018, he became an advisor to MyData.health. Prior to Pfizer, Marc held the position of executive vice president and senior scientist in the life sciences group of OptumInsight, part of United Health Group. Before OptumInsight, he served as Vice President, Global Health Outcomes at Eli Lilly and Company and Vice President, Outcomes Research and Management at Merck & Co., Inc. Marc earned his M.D. from Johns Hopkins University School of Medicine in Baltimore, Maryland. He has held adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health. Marc has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for CMS and the steering committee for the AHRQ Centers for Research and Education on Therapeutics (CERTs) and on the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He has chaired or participated in a number of ISPOR Good Research Practice Taskforces. Marc has written or co-written more than 100 peer-reviewed articles, book chapters, and other publications in health services research, outcomes research, health economics, and health policy. He co-edited “Health Care, Cost, Quality, and Outcomes – ISPOR Book of Terms” which was published in 2003 that has been translated into nine languages. http://scholar.google.ca/citations?user=nfRanQUAAAAJ Specialties: Outomes Reseach, Health Services Research, Health Economics, Health Policy
Interests
None yet.